Dermata Therapeutics Files Proxy Statement Addendum
Ticker: DRMAW · Form: DEFA14A · Filed: Jun 2, 2025 · CIK: 1853816
| Field | Detail |
|---|---|
| Company | Dermata Therapeutics, Inc. (DRMAW) |
| Form Type | DEFA14A |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, shareholder-materials
Related Tickers: DERM
TL;DR
DERM filed more proxy docs, shareholders get more info.
AI Summary
Dermata Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on June 2, 2025. This filing relates to the company's Schedule 14A, indicating it's providing supplementary information to shareholders. The filing does not appear to be a preliminary proxy statement or solicit material under Section 240.14a-12.
Why It Matters
This filing provides additional information to shareholders regarding company matters, which is crucial for informed voting and understanding corporate governance decisions.
Risk Assessment
Risk Level: low — This is a routine filing of additional proxy materials, not indicating any immediate financial or operational risk.
Key Players & Entities
- Dermata Therapeutics, Inc. (company) — Registrant
- 0001641172-25-013238 (filing_id) — Accession Number
- 20250602 (date) — Filing Date
FAQ
What type of filing is this DEFA14A?
This is a Definitive Additional Materials filing for Dermata Therapeutics, Inc., filed under Schedule 14A.
When was this filing submitted to the SEC?
The filing was submitted on June 2, 2025.
What is the company's standard industrial classification?
The company's SIC code is 2834, Pharmaceutical Preparations.
What is Dermata Therapeutics' business address?
The business address is 3525 Del Mar Heights Rd., #322, San Diego, CA 92130.
Does this filing require a fee?
According to the filing, no fee is required.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 2, 2025 regarding Dermata Therapeutics, Inc. (DRMAW).